<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002156</url>
  </required_header>
  <id_info>
    <org_study_id>251B</org_study_id>
    <secondary_id>ISIS 2922-CS3</secondary_id>
    <nct_id>NCT00002156</nct_id>
  </id_info>
  <brief_title>A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR )</brief_title>
  <official_title>A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR )</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To determine the clinically safe and effective dose of intravitreal ISIS 2922 alone and as an&#xD;
      additive antiviral therapy to ganciclovir in AIDS patients with cytomegalovirus (CMV)&#xD;
      retinitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Stage 1 of the study, 20 patients receive one of two doses of ISIS 2922 on days 1, 8, and&#xD;
      15 (Induction) then every 14 days (maintenance), with ganciclovir given daily during both&#xD;
      Induction and Maintenance. Escalation to the second dose does not occur until all patients at&#xD;
      the first dose level have reached their first maintenance dose (day 29). In Stage 2 of the&#xD;
      study, 174 patients are randomized to receive either a) ISIS 2922 at the dose established in&#xD;
      Stage 1 on days 1, 8, and 15 and then every 14 days, with ganciclovir given daily during both&#xD;
      Induction and Maintenance, or b) ganciclovir daily for 14 consecutive days and then a lower&#xD;
      dose as maintenance. Patients may continue to receive ISIS 2922 biweekly if the dose is safe&#xD;
      and their CMV retinitis is clinically controlled. Per 2/8/96 amendment, patients are now in&#xD;
      Stage 2 at 150 mcg.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>194</enrollment>
  <condition>Cytomegalovirus Retinitis</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fomivirsen sodium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganciclovir</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  AIDS.&#xD;
&#xD;
          -  CMV retinitis that is not adequately controlled (previously diagnosed patients with&#xD;
             smoldering CMV retinitis or those with active CMV retinitis borders on indirect&#xD;
             ophthalmoscopy).&#xD;
&#xD;
          -  No more than one previous progression of CMV retinitis.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions in the eye to be treated are excluded:&#xD;
&#xD;
          -  External ocular infection.&#xD;
&#xD;
          -  Other herpetic infections of the retina, toxoplasma retinochoroiditis, or other&#xD;
             disease of the fundus.&#xD;
&#xD;
          -  Ocular condition that will obstruct visualization of the posterior ocular structures.&#xD;
&#xD;
          -  Retinal detachment.&#xD;
&#xD;
          -  Silicone oil in eye.&#xD;
&#xD;
        Patients with the following other symptoms or conditions are excluded:&#xD;
&#xD;
          -  Known or suspected allergy to phosphorothioate oligonucleotides.&#xD;
&#xD;
          -  Syphilis.&#xD;
&#xD;
          -  Retinal pigment epithelial stippling not associated with CMV retinitis.&#xD;
&#xD;
          -  Pseudoretinitis pigmentosa.&#xD;
&#xD;
          -  Chronic diarrhea that would impair absorption of oral ganciclovir.&#xD;
&#xD;
          -  Intolerance to ganciclovir.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Foscarnet or other anti-CMV agents other than ganciclovir.&#xD;
&#xD;
          -  Mellaril.&#xD;
&#xD;
          -  Stelazine.&#xD;
&#xD;
          -  Thorazine.&#xD;
&#xD;
          -  Clofazimine.&#xD;
&#xD;
          -  Ethambutol/fluconazole combination.&#xD;
&#xD;
          -  Investigational medications for CMV retinitis.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Investigational procedures for CMV retinitis.&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
          -  History of surgery to correct retinal detachment in eye to be treated.&#xD;
&#xD;
          -  History of intolerance to ISIS 2922.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Prior ganciclovir implant for CMV retinitis.&#xD;
&#xD;
          -  More than 4 months of prior ganciclovir.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Retina - Vitreous Associates Med Group</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Eye Med Group</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>911052536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Diego Naval Hosp</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of California San Francisco / SF Gen Hosp</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Clara Valley Med Ctr</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Colorado Health Sciences Ctr</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Julio Perez</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Retina</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30327</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Illinois</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Univ Med Ctr</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vitreo - Retinal Consultants</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlotte Eye Ear Nose and Throat Association</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hahnemann Univ Hosp</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Graduate Hosp</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>191461192</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Texas Southwestern Med Ctr of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>752359057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Eye Consultants</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novum Inc</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 1998</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>AIDS-Related Opportunistic Infections</keyword>
  <keyword>Ganciclovir</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Antiviral Agents</keyword>
  <keyword>Cytomegalovirus Retinitis</keyword>
  <keyword>Injections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytomegalovirus Retinitis</mesh_term>
    <mesh_term>Retinitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ganciclovir</mesh_term>
    <mesh_term>Ganciclovir triphosphate</mesh_term>
    <mesh_term>Fomivirsen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

